海角视频

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Enterprise

GSK to invest $30bn in US over next five years in fresh blow to 海角视频's pharma sector

The London-based business said the capital would be deployed over the next five years and would create hundreds of high-skilled American jobs in areas such as AI and advanced digital technologies

GSK said it would invest $30bn into the US(Image: PA Wire/PA Images)

GSK has revealed a fresh strategy to invest $30bn (£22bn) in research and manufacturing infrastructure across the US.

The London-headquartered firm announced the capital would be allocated over the coming five years and would generate hundreds of highly-skilled American positions in sectors including AI and cutting-edge digital technologies, as reported by .

The yearly investment of £4.4bn into the US dwarfs the approximately £1.5bn R&D budget GSK has earmarked for the 海角视频. Nevertheless, the corporation has boosted its 海角视频 expenditure by roughly 50 per cent from £1bn annually just a few years previously.

GSK representatives emphasised the investment strategy did not represent a "no confidence" verdict in the 海角视频 whilst CEO Emma Walmsley remarked the state visit "brings together two countries that have led the world in science and healthcare innovation.

"We are proud to be part of both," Walmsley said.

'It's not good'

The decision places GSK amongst an expanding roster of pharmaceutical firms that have either reduced capital expenditure in the 海角视频 or amplified it in the US.

Last week, Merck abandoned a proposed £1bn research facility in King's Cross after cautioning the 海角视频 was "not internationally competitive", whilst AstraZeneca announced a $50bn investment commitment into the US following the cancellation of plans for a new vaccine manufacturing plant in the 海角视频.

"There's no sugarcoating Merck's decision to leave its planned new HQ in King's Cross. It's not good," said London & Partners CEO Laura Citron. "Merck points to the 海角视频's weaknesses in drug pricing and investment in R&D. Fair and important critiques, which we hear frequently in our conversations with international pharma about setting up in London."